Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Change In Working Capital : $342 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Change In Working Capital?

Chugai Pharmaceutical Co's change in working capital for the quarter that ended in Mar. 2024 was $294 Mil.

Chugai Pharmaceutical Co's change in working capital for the fiscal year that ended in Dec. 2023 was $907 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Chugai Pharmaceutical Co Change In Working Capital Historical Data

The historical data trend for Chugai Pharmaceutical Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Change In Working Capital Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

56.87

-620.66

-730.21

-1,358.72

907.30

Chugai Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															929.15	38.04	-79.09	88.60	294.41

Chugai Pharmaceutical Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $342 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Chugai Pharmaceutical Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

CHGCY:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines

From GuruFocus

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020

T. Rowe Price Japan Fund Comments on Chugai Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 06-19-2020

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020

T. Rowe Price Japan Fund Makes 4 New Buys in 3rd Quarter

By David Goodloe David Goodloe • 10-19-2016

Jean Hynes Adds to Chugai Pharmaceutical Stake

By Kyle Ferguson Kyle Ferguson • 08-22-2016

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

By PRNewswire PRNewswire • 03-02-2023